LAARTregimen
LAARTregimen, an acronym for Low-Activator Antiretroviral Therapy regimen, is a type of antiretroviral therapy (ART) used in the treatment of HIV/AIDS. It is characterized by the use of a low dose of a non-nucleoside reverse transcriptase inhibitor (NNRTI) as the primary antiretroviral drug. The NNRTI used in LAARTregimen is typically efavirenz (EFV) at a dose of 400 mg once daily.
The primary advantage of LAARTregimen is its potential to reduce the risk of drug resistance and improve
LAARTregimen is typically initiated in patients who have not previously received ART or in those who have
The efficacy of LAARTregimen has been demonstrated in various clinical trials, with results showing comparable virologic
In summary, LAARTregimen is a specialized antiretroviral therapy regimen that offers the potential to reduce drug